<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1458</article-id><article-id pub-id-type="doi">10.15690/vramn1458</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ENDOCRINOLOGY: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ЭНДОКРИНОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">A retrospective study of the clinical and laboratory predictors and morphological characteristics of the parathyroid carcinoma</article-title><trans-title-group xml:lang="ru"><trans-title>Многоцентровое ретроспективное исследование клинико-лабораторных предикторов и морфологических характеристик рака околощитовидной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7963-5022</contrib-id><contrib-id contrib-id-type="spin">6279-8247</contrib-id><name-alternatives><name xml:lang="en"><surname>Krupinova</surname><given-names>Julia A.</given-names></name><name xml:lang="ru"><surname>Крупинова</surname><given-names>Юлия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, research associate</p></bio><bio xml:lang="ru"><p>научный сотрудник</p></bio><email>j.krupinova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6687-3240</contrib-id><contrib-id contrib-id-type="spin">9685-1371</contrib-id><name-alternatives><name xml:lang="en"><surname>Voronkova</surname><given-names>Iya A.</given-names></name><name xml:lang="ru"><surname>Воронкова</surname><given-names>Ия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>iya-v@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6935-3187</contrib-id><contrib-id contrib-id-type="spin">9617-7460</contrib-id><name-alternatives><name xml:lang="en"><surname>Ajnetdinova</surname><given-names>Alina R.</given-names></name><name xml:lang="ru"><surname>Айнетдинова</surname><given-names>Алина Ринатовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Doctor-Statistician</p></bio><bio xml:lang="ru"><p>врач-статистик</p></bio><email>9803005@mail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8284-9996</contrib-id><contrib-id contrib-id-type="spin">4089-9502</contrib-id><name-alternatives><name xml:lang="en"><surname>Abrosimov</surname><given-names>Aleksandr Y.</given-names></name><name xml:lang="ru"><surname>Абросимов</surname><given-names>Александр Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>nikitarusskikh@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7876-5105</contrib-id><contrib-id contrib-id-type="spin">7669-3010</contrib-id><name-alternatives><name xml:lang="en"><surname>Kryukova</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Крюкова</surname><given-names>Ирина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>kiv200877@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3317-0108</contrib-id><contrib-id contrib-id-type="spin">4181-8431</contrib-id><name-alternatives><name xml:lang="en"><surname>Lukyanov</surname><given-names>Stanislav V.</given-names></name><name xml:lang="ru"><surname>Лукьянов</surname><given-names>Станислав Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>svluk@rambler.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8849-9595</contrib-id><contrib-id contrib-id-type="spin">7410-9041</contrib-id><name-alternatives><name xml:lang="en"><surname>Veretennikova</surname><given-names>Julia S.</given-names></name><name xml:lang="ru"><surname>Веретенникова</surname><given-names>Юлия Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Clinical Resident</p></bio><bio xml:lang="ru"><p>клинический ординатор</p></bio><email>veretennikova-j@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8954-1633</contrib-id><contrib-id contrib-id-type="spin">7376-4180</contrib-id><name-alternatives><name xml:lang="en"><surname>Tevosyan</surname><given-names>Larisa K.</given-names></name><name xml:lang="ru"><surname>Тевосян</surname><given-names>Лариса Хачатуровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><bio xml:lang="ru"><p>врач-эндокринолог</p></bio><email>tlh_moscou@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5634-7877</contrib-id><contrib-id contrib-id-type="spin">8615-0038</contrib-id><name-alternatives><name xml:lang="en"><surname>Melnichenko</surname><given-names>Galina A.</given-names></name><name xml:lang="ru"><surname>Мельниченко</surname><given-names>Галина Афанасьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>teofrast2000@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><contrib-id contrib-id-type="spin">5624-3875</contrib-id><name-alternatives><name xml:lang="en"><surname>Mokrysheva</surname><given-names>Natalia G.</given-names></name><name xml:lang="ru"><surname>Мокрышева</surname><given-names>Наталья Георгиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Corresponding Member of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, член-корреспондент РАН</p></bio><email>parathyroid.enc@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Moscow Regional Research and Clinical Institute</institution></aff><aff><institution xml:lang="ru">Московский областной научно-исследовательский клинический институт им. М. Ф. Владимирского</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Rostov State Medical University</institution></aff><aff><institution xml:lang="ru">Ростовский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-04-12" publication-format="electronic"><day>12</day><month>04</month><year>2021</year></pub-date><volume>76</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>111</fpage><lpage>124</lpage><history><date date-type="received" iso-8601-date="2020-09-29"><day>29</day><month>09</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-02-16"><day>16</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Издательство "Педиатръ"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2022-04-12"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/1458">https://vestnikramn.spr-journal.ru/jour/article/view/1458</self-uri><abstract xml:lang="en"><p><bold>Background: </bold>there are no specific markers of the parathyroid carcinoma (PC) therefore, the development of algorithms for identifying high-risk patients is an urgent task.</p> <p><bold>Aims:</bold> to determine the clinical and laboratory predictors of PC and to identify the factors of a poor prognosis.</p> <p><bold>Materials and methods:</bold> A multicenter retrospective study included 242 patients with primary hyperparathyroidism (PHPT) who were divided into groups: 162 with adenomas, 30 with аtypical adenomas (АА) and 50 patients with PC. Data collection and analysis was carried out from 2017 to 2020. The primary goal— assessment of the possibility of PС using preoperative laboratory and instrumental data. The group of PC was divided into subgroups: the patients in recurrences (n=17) and remission (n=33). The level of the total calcium, albumin, alkaline phosphatase (ALP), ionized calcium (Ca ++) in the blood were determined on the automatic biochemical analyzer; the level of parathyroid hormone (PTH) by electrochemoluminescent analyzer. The size of the PG determined by the ellipse formula: V (cm<sup>3</sup>) = (A × B × C) × 0.49. Statistical analysis was performed with Statistica 13 and SPSS software packages. For multiple comparisons, the Bonferroni correction was applied.</p> <p><bold>Results:</bold> the group of patients with increased risk of PC include persons with increased level of PTH &gt;443 pg/ml, Ca++ &gt;1.5 mmol/l, total calcium &gt;3.2 mmol/l, ALP &gt;176 IU/L, V of tumors &gt;2.6 cm<sup>3</sup>, largest size &gt;22.5 mm (p &lt;0,001). Heterogeneous structure is more typical to PC compared to the АА (p = 0,004 and р = 0,011), the same applies to indefinite contour (р = 0,001 и р = 0,011). Pathological mitosis is a prognostically unfavorable factor of recurrence of PC (р=0,007).</p> <p><bold>Conclusions:</bold> the patients with PC and AA are characterized with more aggressive course of PHPT compared to the group of adenomas.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование</bold><bold>: </bold>в связи с отсутствием специфичных маркеров рака околощитовидной железы (ОЩЖ) разработка алгоритмов выделения групп повышенного риска представляется актуальной задачей.</p> <p><bold>Цель исследования</bold><bold>:</bold> определить клинико-лабораторные предикторы злокачественных новообразований ОЩЖ и выделить факторы неблагоприятного прогноза.</p> <p><bold>Материалы и методы</bold><bold>:</bold> проведено многоцентровое ретроспективное исследование с включением 242 пациентов с ПГПТ, разделенных на группы карцином (n=50), атипических аденом (АА) (n=30) и аденом (n=162) ОЩЖ. Сбор и анализ данных проводился с 2017 по 2020 гг. Первичная конечная точка — оценка возможности наличия рака ОЩЖ в послеоперационном гистологическом материале с помощью предоперационных лабораторных и инструментальных данных. Дополнительно выделены подгруппы больных с рецидивом (n=17) и с ремиссией заболевания (n=33). Общий кальций, альбумин, щелочная фосфатаза (ЩФ), ионизированный кальций (Са++) в крови определяли на автоматическом биохимическом анализаторе. Анализ крови с определением интактного паратгормона (иПТГ) выполнен на электрохемилюминесцентном анализаторе. Объем ОЩЖ по данным ультразвукового исследования (УЗИ) рассчитывался по формуле эллипса: V(см<sup>3</sup>) = (A × B × C) × 0,49. Статистический анализ проводили с использованием пакетов программ STATISTICA 13 и SPSS. Для множественных сравнений применялась поправка Бонферрони.</p> <p><bold>Результаты</bold><bold>:</bold> в группу повышенного риска наличия рака ОЩЖ на предоперационном этапе следует относить лиц с ПТГ более 443,55 пг/мл, Са++ более 1,5 ммоль/л; альбумин-скорректированным кальцием более 3,2 ммоль/л, ЩФ более 176 ед/л, размером новообразования более 22,5 мм и объемом более 2,6 см<sup>3 </sup>(р &lt;0,001). По данным УЗИ для карцином и АА по сравнению с группой аденом чаще характерна неоднородная структура (p = 0,004 и р = 0,011 соответственно) и нечеткий контур (р = 0,001 и р = 0,011 соответственно). Патологические митозы - прогностически неблагоприятный фактор в отношении рецидива рака ОЩЖ (р=0,007).</p> <p><bold>Заключение</bold><bold>: </bold>для пациентов с карциномой и АА ОЩЖ характерно более агрессивное течение ПГПТ по сравнению с группой аденом.</p></trans-abstract><kwd-group xml:lang="en"><kwd>primary hyperparathyroidism</kwd><kwd>parathyroid cancer</kwd><kwd>parathyroid neoplasms</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>первичный гиперпаратиреоз</kwd><kwd>рак околощитовидной железы</kwd><kwd>новообразования околощитовидных желез</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерства Здравоохранения РФ</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Health of Russia</institution></institution-wrap></funding-source><award-id>АААА-А18-118051590060-2; АААА-А18 -118051590057-2</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: A national cancer data base report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86(3):538–544. doi: https://doi.org/10.1002/(sici)1097-0142(19990801)86:3&lt;538::aid-cncr25&gt;3.0.co;2-k</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–1741. doi: https://doi.org/10.1002/cncr.22599</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Talat N, Schulte K-M. Clinical Presentation, Staging and Long-Term Evolution of Parathyroid Cancer. Ann Surg Oncol. 2010;17(8):2156–2174. doi: https://doi.org/10.1245/s10434-010-1003-6</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1,000 patients: A population-level analysis. Surgery. 2014;156(6):1622–1629. doi: https://doi.org/10.1016/j.surg.2014.08.069</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Villar-del-Moral J, Jiménez-García A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156(5):1132–1144. doi: https://doi.org/10.1016/j.surg.2014.05.014</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin Endocrinol (Oxf). 2016;85(1):29–36. doi: https://doi.org/10.1111/cen.13055</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>van der Zwan JM, Mallone S, van Dijk B, et al. Carcinoma of endocrine organs: results of the RARECARE project. Eur J Cancer. 2012;48(13):1923–1931. doi: https://doi.org/10.1016/j.ejca.2012.01.029</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>James BC, Aschebrook-Kilfoy B, Cipriani N, et al. The incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and pancreas. Ann Surg Oncol. 2016;23(2):424–433. doi: https://doi.org/10.1245/s10434-015-4901-9</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: An update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–3995. doi: https://doi.org/10.1245/s10434-015-4672-3</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schulte KM, Talat N, Galata G, et al. Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. Ann Surg Oncol. 2014;21(6):1891–1897. doi: https://doi.org/10.1245/s10434-014-3530-z</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hsu K-T, Sippel RS, Chen H, Schneider DF, et al. Is central lymph node dissection necessary for parathyroid carcinoma? Surgery. 2014;156(6:)1336–1341; discussion 1341. doi: https://doi.org/10.1016/j.surg.2014.08.005</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;5;S1072-7515(17)30179-5. doi: https://doi.org/10.1016/j.jamcollsurg.2017.01.060</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Brown S, O’Neill C, Suliburk J, et al. Parathyroid carcinoma: Increasing incidence and changing presentation. ANZ J Surg. 2011;81(7–8):528–532. doi: https://doi.org/10.1111/j.1445-2197.2010.05594.x</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol. 2001;2(4):347–354. doi: https://doi.org/10.1007/s11864-001-0028-2</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lo WM, Good ML, Nilubol N, et al. Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma. Ann Surg Oncol. 2018;25(9):2535–2540. doi: https://doi.org/10.1245/s10434-018-6559-6</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485–493. doi: https://doi.org/10.1210/jcem.86.2.7207</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>DeLellis RA, Arnold A, Bilezikian JP WHO classification of tumours of endocrine organs. Parathyroid carcinoma. Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds). 2017. P. 147–158.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Cetani F, Marcocci C, Torregrossa L, Pardi E. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441–R464. doi: https://doi.org/10.1530/ERC-19-0135</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Landry C, Wang T, Asare E. Parathyroid. AJCC Cancer Staging Manual. Springer; 2017. P. 903–910.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Мокрышева Н.Г., Крупинова Ю.А., Мирная С.С. Клинические и лабораторно-инструментальные возможности предоперационной диагностики рака околощитовидных желез // Эндокринная хирургия. — 2017. — Т. 11. — № 3. — С. 136–145. [Mokrysheva NG, Krupinova JA, Mirnaya SS. Clinical, laboratory and instrumental methods of pre-surgical diagnosis of the parathyroid glands cancer. Endocrine Surgery. 2017;11(3):136–145. (In Russ.)] doi: https://doi.org/10.14341/serg20173136-145</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: An update. Cancer Treat Rev. 2020;86:102012. doi: https://doi.org/10.1016/j.ctrv.2020.102012</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ryhänen EM, Leijon H, Metso S, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017;56(7):991–1003. doi: https://doi.org/10.1080/0284186X.2017.1306103</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Schulte K-M, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8(10):612–622. doi: https://doi.org/10.1038/nrendo.2012.102</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Erovic BM, Goldstein DP, Kim D, et al. Parathyroid cancer: outcome analysis of 16 patients treated at the Princess Margaret Hospital. Head Neck. 2013;35(1):35–39. doi: https://doi.org/10.1002/hed.22908</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26(8):716–726. doi: https://doi.org/10.1002/hed.20049</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Liu R, Xia Y, Chen C, et al. Ultrasound combined with biochemical parameters can predict parathyroid carcinoma in patients with primary hyperparathyroidism. Endocrine. 2019;66(3):673–681 doi: https://doi.org/10.1007/s12020-019-02069-7</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Wang L, Han D, Chen W, et al. Non-functional parathyroid carcinoma: A case report and review of the literature. Cancer Biol Ther. 2015;16(11):1569–1576.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Smith RB, Evasovich M, Girod DA, et al. Ultrasound for localization in primary hyperparathyroidism. Otolaryngol Head Neck Surg. 2013;149(3):366–371. doi: https://doi.org/10.1177/0194599813491063</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nam M, Jeong H-S, Shin JH. Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. Acta Radiol. 2017;58(6):670–675. doi: https://doi.org/10.1177/0284185116666418</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Hara H, Igarashi A, Yano Y, et al. Ultrasonographic features of parathyroid carcinoma. Endocr J. 2001;48(2):213–217. doi: https://doi.org/10.1507/endocrj.48.213</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Bondenson L, et al. Parathyroid carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). Pathology and Genetics. Tumors of Endocrine Organs. WHO Classification of Tumours. Lyon: IARC Press; 2004. P. 124–127.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>DeLellis RA, et al. Parathyroid adenoma. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds). WHO classification of tumours of endocrine organs. Lyon: IARC; 2017. P. 153–158.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110(2):255–264. doi: https://doi.org/10.1002/cncr.22790</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011;24 Suppl 2:S78-93. doi: https://doi.org/10.1038/modpathol.2010.132</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Duan K, Mete Ö. Parathyroid Carcinoma: Diagnosis and Clinical Implications. Turk Patoloji Derg. 2015;31(Suppl1):80–97. doi: https://doi.org/10.5146/tjpath.2015.01316</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Katz L, Khalek MA, Crawford B, Kandil E. Robotic-assisted transaxillary parathyroidectomy of an atypical adenoma. Minim Invasive Ther Allied Technol. 2012;21(3):201–205. doi: https://doi.org/10.3109/13645706.2011.581291</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Silva-Figueroa A, Villalobos P, Williams MD, et al. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages. Surgery. 2018;164(5):960–964. doi: https://doi.org/10.1016/j.surg.2018.06.013</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Kar A, Kar T, Dha I, Panda S. Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion. Indian J Pathol Microbiol. 2017; 60(1):125-127 doi: https://doi.org/10.4103/0377-4929.200039</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96(12):3679–3686 doi: https://doi.org/10.1210/jc.2011-1571</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Kebebew E, Arici C, Duk QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136(8):878–885. doi: https://doi.org/10.1001/archsurg.136.8.878</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22(12):3990–3995. doi: https://doi.org/10.1245/s10434-015-4672-3</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Salcuni AS, Cetani F, Guarnieri V, et al. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab. 2018;32(6):877–889. doi: https://doi.org/10.1,016/j.beem.2018.11.002</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Schulte K-M, Gill AJ, Barczynski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19(8):2620–2628. doi: https://doi.org/10.1245/s10434-012-2306-6</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Williams MD, DeLellis RA, Erickson LA, et al. Pathology Data Set for Reporting Parathyroid Carcinoma &amp; Atypical Parathyroid Neoplasm: Recommendations from the International Collaboration on Cancer Reporting. Hum Pathol. 2020;S0046-8177(20)30131-3. doi: https://doi.org/10.1016/j.humpath.2020.07.008.</mixed-citation></ref></ref-list></back></article>
